A Study of LY3209590 in Healthy Participants and Participants With Type 2 Diabetes

Recruitment & Eligibility

Inclusion Criteria

For all study participants:

Must be a male, or a female who cannot become pregnant, and who is either a healthy participant, or who has type 2 diabetes for at least 1 year
Male participants with female partners who can become pregnant must agree to use an effective method of birth control during the study and for 4 months after study drug dosing
Have a body mass index (BMI) of greater than 18.5 kilogram per square meter (kg/m²) and less than or equal to 35 kg/m² at screening
Have blood pressure, pulse rate, blood and urine laboratory test results acceptable for the study
Have venous access sufficient to allow blood sampling

For participants with Type 2 Diabetes Mellitus (T2DM):

Have T2DM controlled with diet and exercise alone or are stable on metformin for at least 30 days
If taken, prescription medications for medical conditions (e.g.antihypertensive agents, aspirin or lipid lowering agents) are stable for at least 4 weeks
Have a hemoglobin A1c (HbA1c) greater than or equal to 7.0% and less than or equal to 9.5%

Exclusion Criteria

For all study participants:

Are currently participating in another clinical study
Have a history of multiple and/or severe allergies to drugs or foods or a history of severe anaphylactic reaction
Have or used to have health problems or laboratory test results or electrocardiogram (ECG) readings that, in the opinion of the doctor, could make it unsafe to participate or could interfere with understanding the results of the study
Have donated blood or have had a loss of 500 milliliters (mL) or more in the last 3 months or have had any blood donation within the last month from screening
Intend to start any new over-the-counter or prescription medications 7 and 14 days before planned dosing

For participants with T2DM:

Have taken any glucose-lowering medications, other than metformin, including insulin, in the past 3 months before screening
Have had more than 1 episode of severe hypoglycemia, within 6 months before entry into the study, or have a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms
Have had a blood transfusion or severe blood loss in the past 3 months, or any blood disorder that could interfere with the understanding of the results of the study
Have received chronic (lasting greater than 14 consecutive days) systemic glucocorticoid therapy (excluding topical, intra-articular, and inhaled preparations) in the 3 past months, or have received any glucocorticoid therapy within 30 days before screening

Study & Design

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Placebo (sterile saline) administered SC.
LY3209590	LY3209590	LY3209590 administered subcutaneously (SC).
Insulin Glargine (Lantus)	Insulin Glargine	Insulin Glargine administered SC.

Primary Outcome Measures

Name	Time	Method
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Baseline through Day 31

Secondary Outcome Measures

Name	Time	Method
Pharmacokinetics: Area Under The Concentration Curve Zero to Infinity (AUC[0-∞]) of LY3209590	Baseline through Day 31
Pharmacodynamics: Average Glucose from 8-Point Glucose Profiles in Participants with T2DM treated with Placebo or LY3209590	Day 3

Recruitment & Eligibility